PM 54
Alternative Names: PM-54Latest Information Update: 31 Dec 2025
At a glance
- Originator PharmaMar
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; RNA polymerase II inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Dec 2025 US FDA approves IND application for PM 54 in Solid tumours
- 18 Dec 2025 PharmaMar plans a phase I/II trial for Solid tumours, including Malignant melanoma, Endometrial cancer, Neuroendocrine tumours and Mesothelioma (Combination therapy, Late-stage disease) in USA (IV)
- 14 Oct 2025 PM 54 is still in phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy) in Belgium, USA and Spain (IV) (NCT05841563) (PharmaMar pipeline; October 2025)